Key statistics
On Friday, Design Therapeutics Inc (DSGN:NSQ) closed at 10.07, -8.20% below its 52-week high of 10.97, set on Jan 27, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 10.10 |
|---|---|
| High | 10.21 |
| Low | 9.91 |
| Bid | 7.20 |
| Offer | 12.00 |
| Previous close | 10.05 |
| Average volume | 193.90k |
|---|---|
| Shares outstanding | 56.96m |
| Free float | 36.47m |
| P/E (TTM) | -- |
| Market cap | 573.63m USD |
| EPS (TTM) | -1.19 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Announcements
- Design Therapeutics to Participate in Upcoming Investor Conferences
- Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
- Design Therapeutics Appoints Justin Gover to Board of Directors
- Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
- Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results
- Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
- Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
- Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
- Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
- Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
More ▼
